Benevolent Platform Precision Medicine slide image

Benevolent Platform Precision Medicine

Abl target hypothesis has been validated using complex cell-based systems The SITraN assay: a humanised cell model of ALS Working in collaboration with academic experts at SITraN who have developed a patient cell derived assay system ¡Astrocytes (via induced progenitors) obtained from genetically-diverse ALS patients cause motor neuron toxicity in a co-culture assay Can test biological hypotheses by measuring the rescue of motor neuron survival Benevolent proprietary CNS penetrant Abl inhibitors are neuroprotective in this assay Induced Patient Fibroblasts Neuronal Progenitor Cell Induced Astrocytes Motor Neurons uron survival % motor neuron -50 150- 100- 50- Healthy donor ¡Astro/DMSO C9orf72 Patient iAstro/DMSO C9orf72 Patient iAstro/10uM Riluzole C9orf72 Patient iAstro/10uM Gefitinib Non-CNS penetrant TK inhibitor C9orf72 Patient iAstro/1uM BEN-A BAI CNS penetrant Abl inhibitor Benevolent 48
View entire presentation